The estimated Net Worth of Paul J Clancy is at least $17.8 Million dollars as of 20 May 2022. Mr. Clancy owns over 1,585 units of Incyte stock worth over $413,438 and over the last 17 years he sold INCY stock worth over $16,820,553. In addition, he makes $536,489 as Independent Director at Incyte.
Paul has made over 29 trades of the Incyte stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 1,585 units of INCY stock worth $100,061 on 20 May 2022.
The largest trade he's ever made was exercising 99,030 units of Incyte stock on 16 September 2013 worth over $5,556,573. On average, Paul trades about 2,993 units every 46 days since 2007. As of 20 May 2022 he still owns at least 6,549 units of Incyte stock.
You can see the complete history of Mr. Clancy stock trades at the bottom of the page.
Paul J. Clancy is an Independent Director of Incyte Corporation. Mr. Clancy has more than 30 years of experience in financial management and strategic business planning, and has served as the Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc., a biopharmaceutical company, since July 2017. Prior to joining Alexion, Mr. Clancy served as Executive Vice President, Finance and Chief Financial Officer of Biogen Inc. (formerly known as Biogen Idec Inc.), a biotechnology company, from August 2007 until June 2017. He also served as Senior Vice President of Finance of Biogen, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to the 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation to form Biogen, Mr. Clancy was the Vice President of Portfolio Management of Biogen. He joined Biogen in 2001 as Vice President of U.S. Marketing. Before Biogen, Mr. Clancy spent 13 years at PepsiCo Inc., a food and beverage company, serving in a variety of financial and general management positions, including Vice President and General Manager of their Great West Business Unit.
As the Independent Director of Incyte, the total compensation of Paul Clancy at Incyte is $536,489. There are 14 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.
Paul Clancy is 58, he's been the Independent Director of Incyte since 2015. There are 12 older and 12 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
Paul's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B..., and Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: